Molecular Formula | C22H22FN3O3 |
Molar Mass | 395.43 |
Density | 1.33±0.1 g/cm3(Predicted) |
Appearance | powder |
Color | white to beige |
pKa | 12.07±0.40(Predicted) |
Storage Condition | 2-8°C |
In vitro study | AZD2461 has a lower affinity for Pgp than Olaparib. |
In vivo study | AZD2461 acts on KB1P tumor T6-28 against Olaparib, increasing the expression of Mdr1b by 80 times, and does not inhibit Pgp. Short-term treatment of mice bearing KB1P tumors with AZD2461 induced a loss of 53BP1 expression. AZD2461 was well tolerated with long-term treatment, and the mean relapse-free survival was doubled. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.529 ml | 12.644 ml | 25.289 ml |
5 mM | 0.506 ml | 2.529 ml | 5.058 ml |
10 mM | 0.253 ml | 1.264 ml | 2.529 ml |
5 mM | 0.051 ml | 0.253 ml | 0.506 ml |
biological activity | AZD2461 is a new type of PARP inhibitor, which has lower affinity for Pgp than Olaparib. Phase 1. |
target | TargetValue PARP |
Target | Value |
in vitro studies | AZD2461 acts on Pgp with lower affinity than Olaparib. |
in vivo studies | AZD2461 act on anti-Olaparib KB1P tumor T6-28, increase Mdr1b expression by 80 times, and do not inhibit Pgp. AZD2461 short-term treatment of mice carrying KB1P tumor induced 53BP1 expression loss. AZD2461 long-term treatment, it is well tolerated, and the average relapse-free survival is doubled. |